JP2007536200A - リポペプチド抗生物質誘導体の組成物およびその使用方法 - Google Patents

リポペプチド抗生物質誘導体の組成物およびその使用方法 Download PDF

Info

Publication number
JP2007536200A
JP2007536200A JP2006520201A JP2006520201A JP2007536200A JP 2007536200 A JP2007536200 A JP 2007536200A JP 2006520201 A JP2006520201 A JP 2006520201A JP 2006520201 A JP2006520201 A JP 2006520201A JP 2007536200 A JP2007536200 A JP 2007536200A
Authority
JP
Japan
Prior art keywords
compound
acid
amphomycin
substituted
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006520201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536200A5 (https=
Inventor
デール アール． キャメロン，
ビンセント エー． ボイド，
リチャード エー． リーズ，
ウィリアム ブイ． カラン，
ドナルド ビー． ボーダーズ，
パウロ ダブリュー． エム． スガルビ，
シャーリー エー． ワコウィッチ−スガルビ，
マシュー ノドウェル，
ユチェン チェン，
チ チャ，
ドミニク ドゥグール，
Original Assignee
ミジェニックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミジェニックス インコーポレイテッド filed Critical ミジェニックス インコーポレイテッド
Publication of JP2007536200A publication Critical patent/JP2007536200A/ja
Publication of JP2007536200A5 publication Critical patent/JP2007536200A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006520201A 2003-07-17 2004-06-28 リポペプチド抗生物質誘導体の組成物およびその使用方法 Pending JP2007536200A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48833103P 2003-07-17 2003-07-17
US60/488,331 2003-07-17
US56491204P 2004-04-23 2004-04-23
US60/564,912 2004-04-23
PCT/US2004/021039 WO2005000878A2 (en) 2003-06-26 2004-06-28 Compositions of lipopeptide antibiotic derivatives and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2007536200A true JP2007536200A (ja) 2007-12-13
JP2007536200A5 JP2007536200A5 (https=) 2010-10-28

Family

ID=36203969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006520201A Pending JP2007536200A (ja) 2003-07-17 2004-06-28 リポペプチド抗生物質誘導体の組成物およびその使用方法

Country Status (11)

Country Link
US (1) US7868135B2 (https=)
EP (2) EP2147925A1 (https=)
JP (1) JP2007536200A (https=)
CN (1) CN1839150A (https=)
AU (1) AU2004252174A1 (https=)
CA (1) CA2530063A1 (https=)
EA (1) EA010294B1 (https=)
IL (1) IL172647A0 (https=)
NZ (1) NZ544750A (https=)
WO (1) WO2005000878A2 (https=)
ZA (1) ZA200600008B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518006A (ja) * 2009-02-16 2012-08-09 セレニス セラピューティクス エスエー アポリポタンパクａ−ｉ模倣物
WO2020017085A1 (ja) * 2018-07-20 2020-01-23 藤本化学製品株式会社 アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
JP2020513036A (ja) * 2017-04-05 2020-04-30 レボリューション メディシンズ インコーポレイテッドＲｅｖｏｌｕｔｉｏｎ Ｍｅｄｉｃｉｎｅｓ，Ｉｎｃ． 協同的結合に関与する化合物及びその使用
JP2020203902A (ja) * 2018-07-20 2020-12-24 藤本化学製品株式会社 アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
US11644460B2 (en) 2010-12-28 2023-05-09 Revolution Medicines, Inc. Identifying new therapeutic agents
US11987590B2 (en) 2015-01-09 2024-05-21 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092632A2 (en) * 2006-02-09 2007-08-16 Elevance Renawable Sciences, Inc. Surface coating compositions and methods
US20080033026A1 (en) * 2006-02-09 2008-02-07 Zullo Jill L Antimicrobial compositions, methods and systems
GB0821540D0 (en) * 2008-11-25 2008-12-31 Merlion Pharmaceuticals Pte Ltd Lipopeptide compounds and their use
DE102009060102A1 (de) * 2009-12-21 2011-06-22 Martin-Luther-Universität Halle-Wittenberg, 06108 Derivatisierungsreagenzien zur tandem-massenspektrometrischen Quantifizierung von Proteinen
MX2012010381A (es) * 2010-03-09 2012-11-23 Merck Canada Inc Lipoglicopeptidos en puente que potencian la actividad de antibacterianos de beta-lactama.
ES2374779B1 (es) * 2010-03-10 2012-12-27 Universidad De Barcelona Compuestos péptidicos útiles como agentes antibacterianos.
TWI642684B (zh) * 2011-05-27 2018-12-01 Ｒｑｘ製藥股份有限公司 廣效性抗生素
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
EP2703410B1 (en) * 2012-08-28 2015-10-14 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie Jagaricin, derivatives, and uses thereof
EA201590871A1 (ru) 2012-11-21 2015-11-30 АрКьюЭкс ФАРМАСЪЮТИКЛС, ИНК. Макроциклические антибиотики широкого спектра действия
BR112016027232A2 (pt) 2014-05-20 2018-06-26 Genentech Inc antibióticos macrocíclicos de amplo espectro
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
CN104557743A (zh) * 2014-12-02 2015-04-29 南京邮电大学 一类包含不饱和脂肪酸结构的抗白色念珠菌药物及其制备方法
CN104817619B (zh) * 2015-04-23 2018-07-17 浙江大学 抗菌化合物及其应用
CN105231000B (zh) * 2015-09-25 2020-01-07 广东海洋大学 一种利用水产品下脚料生产抗菌营养复合型饲料添加剂的方法
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN109593808B (zh) * 2017-09-30 2022-10-04 上海医药工业研究院 达托霉素发酵培养基及其制备方法
WO2020031083A1 (en) * 2018-08-06 2020-02-13 KHAN, Khalid Antimicrobial formulations comprising vancomycin or tobramycin
CN111434775B (zh) * 2019-01-11 2022-12-06 上海医药工业研究院 一种发酵制备达托霉素的方法
ES2961566T3 (es) 2019-05-28 2024-03-12 Hoffmann La Roche Antibióticos macrocíclicos de amplio espectro
RU2762182C1 (ru) * 2020-12-08 2021-12-16 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения
CN112625106B (zh) * 2021-01-13 2023-03-31 兰州大学 一种抗菌多肽化合物、合成方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0797394A (ja) * 1993-06-08 1995-04-11 Hoechst Ag 薬理活性を有するアクチノプラネスｓｐ．由来のリポペプチド、その生産方法およびその使用
JPH07278186A (ja) * 1994-03-30 1995-10-24 Hoechst Ag リポペプチド誘導体、その製造法およびその使用
WO2002005837A1 (en) * 2000-07-17 2002-01-24 Intrabiotics Pharmaceuticals, Inc. Antimicrobial sulfonamide derivatives of lipopeptide antibiotics

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923544A (en) 1959-07-21 1963-04-10 Takeda Pharmaceutical A new antibiotic-glumamycin
US3057779A (en) 1960-03-14 1962-10-09 American Cyanamid Co Antibiotic and production thereof
US3639582A (en) 1967-04-14 1972-02-01 Zaidan Hojin Biseibutsu Antibiotic laspartomycin
DE1800363A1 (de) 1967-10-04 1969-07-03 Shionogi & Co Tsushimycin und seine Herstellung
FR2124060B1 (https=) 1971-02-02 1974-04-12 Rhone Poulenc Sa
IL61604A (en) 1977-07-22 1981-10-30 Baxter Travenol Lab Flexible collapsible containers
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
CA1315229C (en) 1987-06-10 1993-03-30 Eli Lilly And Company Chromatographic purification process
US4994270A (en) 1988-04-11 1991-02-19 Eli Lilly And Company A54145 antibiotics and process for their production
US5039789A (en) 1988-04-11 1991-08-13 Eli Lilly And Company A54145 cyclic peptides
US4977083A (en) 1988-04-11 1990-12-11 Eli Lilly And Company Processes for preparing A54145 compounds
US5028590A (en) 1988-04-11 1991-07-02 Eli Lilly And Company Derivatives of A54145 cyclic peptides
EP0933422A4 (en) 1996-06-13 2005-02-02 Fujisawa Pharmaceutical Co CYCLIC LIPOPEPTIDE ACYLASE
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US6750199B2 (en) 2000-07-17 2004-06-15 Micrologix Biotech Inc. Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
US7125844B2 (en) 2002-01-03 2006-10-24 Migenix Inc. Dab9 derivatives of lipopeptide antibiotics and methods of making and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0797394A (ja) * 1993-06-08 1995-04-11 Hoechst Ag 薬理活性を有するアクチノプラネスｓｐ．由来のリポペプチド、その生産方法およびその使用
JPH07278186A (ja) * 1994-03-30 1995-10-24 Hoechst Ag リポペプチド誘導体、その製造法およびその使用
WO2002005837A1 (en) * 2000-07-17 2002-01-24 Intrabiotics Pharmaceuticals, Inc. Antimicrobial sulfonamide derivatives of lipopeptide antibiotics

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518006A (ja) * 2009-02-16 2012-08-09 セレニス セラピューティクス エスエー アポリポタンパクａ−ｉ模倣物
JP2015110677A (ja) * 2009-02-16 2015-06-18 セレニス セラピューティクス ホールディング エスアー アポリポタンパクａ−ｉ模倣物
US11644460B2 (en) 2010-12-28 2023-05-09 Revolution Medicines, Inc. Identifying new therapeutic agents
US11987590B2 (en) 2015-01-09 2024-05-21 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
JP2020513036A (ja) * 2017-04-05 2020-04-30 レボリューション メディシンズ インコーポレイテッドＲｅｖｏｌｕｔｉｏｎ Ｍｅｄｉｃｉｎｅｓ，Ｉｎｃ． 協同的結合に関与する化合物及びその使用
WO2020017085A1 (ja) * 2018-07-20 2020-01-23 藤本化学製品株式会社 アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
JP2020011932A (ja) * 2018-07-20 2020-01-23 藤本化学製品株式会社 アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
JP2020203902A (ja) * 2018-07-20 2020-12-24 藤本化学製品株式会社 アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
JP7296636B2 (ja) 2018-07-20 2023-06-23 藤本化学製品株式会社 アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
US12209106B2 (en) 2018-07-20 2025-01-28 Fujimoto Chemicals Co., Ltd. Alkoxyphenyl derivatives, protected nucleosides and protected nucleotides, method for producing oligonucleotides, and method for removing substituents

Also Published As

Publication number Publication date
EA010294B1 (ru) 2008-08-29
WO2005000878A3 (en) 2005-06-16
EP1656390A2 (en) 2006-05-17
IL172647A0 (en) 2006-04-10
EP2147925A1 (en) 2010-01-27
WO2005000878A2 (en) 2005-01-06
NZ544750A (en) 2009-06-26
WO2005000878A8 (en) 2006-06-08
US20050153876A1 (en) 2005-07-14
US7868135B2 (en) 2011-01-11
CN1839150A (zh) 2006-09-27
ZA200600008B (en) 2007-09-26
CA2530063A1 (en) 2005-01-06
AU2004252174A1 (en) 2005-01-06
EA200600280A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
JP2007536200A (ja) リポペプチド抗生物質誘導体の組成物およびその使用方法
JP2007536200A5 (https=)
RU2730012C2 (ru) Производные полимиксина и их применение в комбинированной терапии совместно с различными антибиотиками
RU2428429C2 (ru) Пептидные антибиотики и способы их получения
US11046730B2 (en) Antimicrobial compositions
TW200936153A (en) Short fatty acid tail polymyxin derivatives and uses thereof
BG65926B1 (bg) Кахалалидни съединения
US20100137199A1 (en) Dab9 DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING AND USING THE SAME
EP2548883A2 (en) Peptide compounds that can be used as antibacterial agents
CN102046652B (zh) 来自Actinomadura namibiensis的高度桥联的肽
Zhang et al. Naturally occurring antitubercular cyclic peptides
EP1809657A1 (de) Cyclische nonapeptidamide
JP4817335B2 (ja) 新規抗菌性ペプチド
MXPA06000525A (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
WO2001005814A1 (en) Pseudomycin n-acyl side-chain analogs
JP3874372B2 (ja) 制癌剤の効果増強剤
US20030211980A1 (en) Antimicrobial agents
CN120757608A (zh) 一种抗菌肽及其制备方法与应用
JPH11263797A (ja) Ｎ―置換グリシン残基を含有するデプシペプチド

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110902